Polymorphisms of serotonin neurotransmission and their effects on antipsychotic drug action

Pharmacogenomics

Volumn 15, Issue 12, 2014, Pages 1599-1609

  Tang, Hao ^a,b   Mcgowan, Olga O ^c   Reynolds, Gavin P ^b  

^a Second People's Hospital of Yunnan Province   (China)

^b SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

^c WISHAW GENERAL HOSPITAL   (United Kingdom)

Author keywords

5 HT receptors; 5 hydroxytryptamine; antipsychotic drugs; gene; neurotransmitters; schizophrenia; side effects; symptom response

Indexed keywords

DNA; NEUROLEPTIC AGENT; SEROTONIN; SEROTONIN 1B RECEPTOR; SEROTONIN 2A ANTAGONIST; SEROTONIN 2C RECEPTOR; SEROTONIN 4 RECEPTOR; SEROTONIN 6 RECEPTOR; SEROTONIN 7 RECEPTOR; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER;

DNA METHYLATION; DNA POLYMORPHISM; DRUG RESPONSE; EXTRAPYRAMIDAL SYMPTOM; GENE; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HTR1A GENE; HTR2A GENE; HTR2C GENE; HUMAN; MAOA GENE; NEUROTRANSMISSION; PHARMACOGENETICS; PROTEIN METABOLISM; REGULATORY MECHANISM; REVIEW; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SLC6A4 GENE; TPH1 GENE; WEIGHT GAIN; DRUG EFFECTS; GENETICS; NEURODEGENERATIVE DISEASES; PATHOLOGY; PERSONALIZED MEDICINE; SYNAPTIC TRANSMISSION;

ANTIPSYCHOTIC AGENTS; HUMANS; INDIVIDUALIZED MEDICINE; NEURODEGENERATIVE DISEASES; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, SEROTONIN; SEROTONIN; SYNAPTIC TRANSMISSION;

EID: 84908130762     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.14.111     Document Type: Review

References (70)

1. Scharfetter J. Pharmacogenetics of dopamine receptors and response to antipsychotic drugs in schizophrenia-An update. Pharmacogenomics 5(6), 691-698 (2004).
2. Shiroma PR, Geda YE, Mrazek DA. Pharmacogenomic implications of variants of monoaminergic-related genes in geriatric psychiatry. Pharmacogenomics 11(9), 1305-1330 (2010).
3. Reynolds GP. The pharmacogenetics of antipsychotic treatment. Handb. Exp. Pharmacol. 212, 213-239 (2012).
4. Brandl EJ, Kennedy JL, Müller DJ. Pharmacogenetics of antipsychotics. Can. J. Psychiatry 59(2), 76-88 (2014).
5. Reynolds GP. Receptor mechanisms of antipsychotic drug action in bipolar disorder-focus on asenapine. Ther. Adv. Psychopharmacol. 1(6), 197-204 (2011).
6. Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O'Laughlin IA, Meltzer HY. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J. Neurochem. 76(5), 1521-1531 (2001).
7. Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 27(7), 1159-1172 (2003).
8. Gouzoulis-Mayfrank E, Heekeren K, Neukirch A, et al. Psychological effects of (S)-ketamine and N, N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers. Pharmacopsychiatry 38(6), 301-311 (2005).
9. Travis MJ, Busatto GF, Pilowsky LS, et al. 5-HT2A receptor blockade in patients with schizophrenia treated with risperidone or clozapine. A SPET study using the novel 5-HT2A ligand 123I-5-I-R-91150. Br. J. Psychiatry 173, 236-241 (1998).
10. Reimold M, Solbach C, Noda S, et al. Occupancy of dopamine D(1), D(2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol. Psychopharmacology (Berl.) 190(2), 241-249 (2007).
11. Schreiber R, Newman-Tancredi A. Improving cognition in schizophrenia with antipsychotics that elicit neurogenesis through 5-HT1A receptor activation. Neurobiol. Learn. Mem. 110, 72-80 (2014).
12. Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatment-pharmacological mechanisms. Pharmacol. Ther. 125(1), 169-179 (2010
13. Zill P, Buttner A, Eisenmenger W, Muller J, Moller HJ, Bondy B. Predominant expression of tryptophan hydroxylase 1 mRNA in the pituitary: a postmortem study in human brain. Neuroscience 159(4), 1274-1282 (2009).
14. Nakamura K, Sugawara Y, Sawabe K, et al. Late developmental stage-specific role of tryptophan hydroxylase 1 in brain serotonin levels. J. Neurosci. 2(2), 530-534 (2006).
15. Schuhmacher A, Becker T, Rujescu D, et al. Investigation of tryptophan hydroxylase 2 (TPH2) in schizophrenia and in the response to antipsychotics. J. Psychiatr. Res. 46(8), 1073-1080 (2012).
16. Al-Janabi I, Arranz MJ, Blakemore AI, et al. Association study of serotonergic gene variants with antipsychotic-induced adverse reactions. Psychiatr. Genet. 19(6), 305-311 (2009).
17. Anttila S, Kampman O, Illi A, Rontu R, Lehtimäki T, Leinonen E. Association between 5-HT2A, TPH1 and GNB3 genotypes and response to typical neuroleptics: a serotonergic approach. BMC Psychiatry 7, 22 (2007).
18. Nowrouzi B, Souza RP, Zai C, et al. Finite mixture regression model analysis on antipsychotics induced weight gain: investigation of the role of the serotonergic genes. Eur. Neuropsychopharmacol. 23(3), 224-228 (2013).
19. Jönsson EG, Goldman D, Spurlock G, et al. Tryptophan hydroxylase and catechol-O-methyltransferase gene polymorphisms: relationships to monoamine metabolite concentrations in CSF of healthy volunteers. Eur. Arch. Psychiatry Clin. Neurosci. 247(6), 297-302 (1997).
20. Heils A, Teufel A, Petri S, et al. Allelic variation of human serotonin transporter gene expression. J. Neurochem. 66(6), 2621-2624 (1996).
21. Lovejoy EA, Scott AC, Fiskerstrand CE, Bubb VJ, Quinn JP. The serotonin transporter intronic VNTR enhancer correlated with a predisposition to affective disorders has distinct regulatory elements within the domain based on the primary DNA sequence of the repeat unit. Eur. J. Neurosci. 17(2), 417-420 (2003).
22. Klenova E, Scott AC, Roberts J, et al. YB-1 and CTCF differentially regulate the 5-HTT polymorphic intron 2 enhancer which predisposes to a variety of neurological disorders. J. Neurosci. 24(26), 5966-5973 (2004).
23. Haddley K, Vasiliou AS, Ali FR, Paredes UM, Bubb VJ, Quinn JP. Molecular genetics of monoamine transporters: relevance to brain disorders. Neurochem. Res. 33(4), 652-667 (2008).
24. Ali FR, Vasiliou SA, Haddley K, et al. Combinatorial interaction between two human serotonin transporter gene variable number tandem repeats and their regulation by CTCF. J. Neurochem. 112(1), 296-306 (2010).
25. Fiskerstrand CE, Lovejoy EA, Quinn JP. An intronic polymorphic domain often associated with susceptibility to affective disorders has allele dependent differential enhancer activity in embryonic stem cells. FEBS Lett. 458(2), 171-174 (1999).
26. MacKenzie A, Quinn JP. A serotonin transporter gene intron 2 polymorphic region, correlated with affective disorders, has allele-dependent differential enhancer-like properties in the mouse embryo. PNAS 96(26), 15251-15255 (1999).
27. Hu XZ, Lipsky RH, Zhu G, et al. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am. J. Hum. Genet. 78(5), 815-826 (2006).
28. Lemonde S, Turecki G, Bakish D, et al. Impaired repression at a 5-HT1a receptor gene polymorphism associated with MDD and suicide. J. Neurosci. 23, 8788-8799 (2003).
29. Parsons MJ, D'Souza UM, Arranz MJ, Kerwin RW, Makoff AJ. The-1438A/G polymorphism in the 5-hydroxytryptamine type 2A receptor gene affects promoter activity. Biol. Psychiatry 56(6), 406-410 (2004).
30. Hazelwood LA, Sanders-Bush E. His452Tyr polymorphism in the human 5-HT2A receptor destabilizes the signaling conformation. Mol. Pharmacol. 66(5), 1293-1300 (2004).
31. Yuan X, Yamada K, Ishiyama-Shigemoto S, Koyama W, Nonaka K. Identification of polymorphic loci in the promoter region of the serotonin 5-HT2C receptor gene and their association with obesity and Type II diabetes. Diabetologia 43(3), 373-376 (2000).
32. Hill MJ, Reynolds GP. 5-HT2C receptor gene polymorphisms associated with antipsychotic drug action alter promoter activity. Brain Res. 1149, 14-17 (2007).
33. Okada M, Northup JK, Ozaki N, Russell JT, Linnoila M, Goldman D. Modification of human 5-HT(2C) receptor function by Cys23Ser, an abundant, naturally occurring amino-Acid substitution. Mol. Psychiat. 9, 55-64 (2004).
34. Sabol SZ, Hu S, Hamer D. A functional polymorphism in the monoamine oxidase A gene promoter. Hum. Genet. 103(3), 273-279 (1998).
35. Hotamisligil GS, Breakefield XO. Human monoamine oxidase A gene determines levels of enzyme activity. Am. J. Hum. Genet. 49(2), 383-392 (1991).
36. Arranz MJ, Munro J, Birkett J, et al. Pharmacogenetic prediction of clozapine response. Lancet 355(9215), 1615-1616 (2000).
37. Wang L, Yu L, He G, et al. Response of risperidone treatment may be associated with polymorphisms of HTT gene in Chinese schizophrenia patients. Neurosci. Lett. 414(1), 1-4 (2007).
38. Dolzan V, Serretti A, Mandelli L, Koprivsek J, Kastelic M, Plesnicar BK. Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes. Prog. Neuropsychopharmacol. Biol. Psychiatry 32(6), 1562-1566 (2008).
39. Vázquez-Bourgon J, Arranz MJ, Mata I, et al. Serotonin transporter polymorphisms and early response to antipsychotic treatment in first episode of psychosis. Psychiatry Res. 175(3), 189-194 (2010
40. Tsai HT, Caroff SN, Miller del D, et al. A candidate gene study of tardive dyskinesia in the CATIE schizophrenia trial. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 153B(1), 336-340 (2010).
41. Zai CC, Tiwari AK, Mazzoco M, et al. Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia. J. Psychiatr. Res. 47(11), 1760-1765 (2013).
42. Reynolds GP, Arranz B, Templeman LA, Fertuzinhos S, San L. Effect of 5 HT1A receptor gene polymorphism on negative and depressive symptom response to antipsychotic treatment of drug-naive psychotic patients. Am. J. Psychiatry 163, 1826-1829 (2006).
43. Wang L, Fang C, Zhang A, et al. The-1019 C/G polymorphism of the 5-HT(1)A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients. J. Psychopharmacol. 22(8), 904-909 (2008).
44. Mossner R, Schuhmacher A, Kühn KU, et al. Functional serotonin 1A receptor variant influences treatment response to atypical antipsychotics in schizophrenia. Pharmacogenet. Genomics 19(1), 91-94 (2009).
45. Polesskaya OO, Aston C, Sokolov BP. Allele C-specific methylation of the 5-HT2A receptor gene: evidence for correlation with its expression and expression of DNA methylase DNMT1. J. Neurosci. Res. 83(3), 362-273 (2006).
46. Reist C, Mazzanti C, Vu R, Fujimoto K, Goldman D. Inter-relationships of intermediate phenotypes for serotonin function, impulsivity, and a 5-HT2A candidate allele: His452Tyr. Mol. Psychiatry 9(9), 871-878 (2004).
47. Zhang JP, Malhotra AK. Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction. Expert Opin. Drug Metab. Toxicol. 7(1), 9-37 (2011).
48. Lane HY, Chang YC, Chiu CC, Chen ML, Hsieh MH, Chang WH. Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene. Am. J. Psychiatry 159(9), 1593-1595 (2002).
49. Hamdani N, Bonnière M, Adès J, Hamon M, Boni C, Gorwood P. Negative symptoms of schizophrenia could explain discrepant data on the association between the 5-HT2A receptor gene and response to antipsychotics. Neurosci. Lett. 377(1), 69-74 (2005).
50. Ellingrod VL, Lund BC, Miller D, et al. 5-HT2A receptor promoter polymorphism,-1438G/A and negative symptom response to olanzapine in schizophrenia. Psychopharmacol. Bull. 37(2), 109-112 (2003).
51. Need AC, Keefe RS, Ge D, et al. Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis. Eur. J. Hum. Genet. 17(7), 946-957 (2009).
52. Lerer B, Segman RH. Pharmacogenetics of antipsychotic therapy: pivotal research issues and the prospects for clinical implementation. Dialogues Clin. Neurosci. 8(1), 85-94 (2006).
53. Gunes A, Scordo MG, Jaanson P, Dahl ML. Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-Treated schizophrenic patients. Psychopharmacology (Berl.) 190(4), 479-484 (2007).
54. Ujike H, Nomura A, Morita Y, et al. Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study. J. Clin. Psychiatry 69(9), 1416-1422 (2008).
55. Reynolds GP, Templeman LA, Zhang ZJ. The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry 29(6), 1021-1028 (2005).
56. Reynolds GP, Zhang ZJ, Zhang XB. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 359(9323), 2086-2087 (2002).
57. Reynolds GP. Pharmacogenetic aspects of antipsychotic drug-induced weight gain-A critical review. Clin. Psychopharmacol. Neurosci. 10(2), 71-77 (2012).
58. Risselada AJ, Vehof J, Bruggeman R, et al. Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics: a replication study. Pharmacogenomics J. 12(1), 62-67 (2012).
59. Yevtushenko OO, Cooper SJ, O'Neill R, Doherty JK, Woodside JV, Reynolds GP. Influence of 5-HT2C receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophrenia. Br. J. Psychiatry 192(6), 424-428 (2008).
60. Lane HY, Lin CC, Huang CH, Chang YC, Hsu SK, Chang WH. Risperidone response and 5-HT6 receptor gene variance: genetic association analysis with adjustment for nongenetic confounders. Schizophr. Res. 67(1), 63-70 (2004).
61. Ikeda M, Yamanouchi Y, Kinoshita Y, et al. Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia. Pharmacogenomics 9(10), 1437-1443 (2008).
62. Souza RP, De Luca V, Muscettola G, et al. Association of antipsychotic induced weight gain and body mass index with GNB3 gene: a meta-Analysis. Prog. Neuropsychopharmacol. Biol. Psychiatry 32(8), 1848-1853 (2008).
63. Greenbaum L, Smith RC, Rigbi A, et al. Further evidence for association of the RGS2 gene with antipsychotic-induced parkinsonism: protective role of a functional polymorphism in the 3'-untranslated region. Pharmacogenomics J. 9(2), 103-110 (2009).
64. Higa M, Ohnuma T, Maeshima H, et al. Association analysis between functional polymorphism of the rs4606 SNP in the RGS2 gene and antipsychotic-induced Parkinsonism in Japanese patients with schizophrenia: results from the Juntendo University Schizophrenia Projects (JUSP). Neurosci. Lett. 469(1), 55-59 (2010
65. Lane HY, Liu YC, Huang CL, et al. RGS4 polymorphisms predict clinical manifestations and responses to risperidone treatment in patients with schizophrenia. J. Clin. Psychopharmacol. 28(1), 64-68 (2008).
66. Illi A, Mattila KM, Kampman O, et al. Catechol-O-methyltransferase and monoamine oxidase A genotypes and drug response to conventional neuroleptics in schizophrenia. J. Clin. Psychopharmacol. 23(5), 429-434 (2003).
67. Melas PA, Rogdaki M, Osby U, Schalling M, Lavebratt C, Ekstrom TJ. Epigenetic aberrations in leukocytes of patients with schizophrenia: association of global DNA methylation with antipsychotic drug treatment and disease onset. FASEB J. 26(6), 2712-2718 (2012).
68. Abdolmaleky HM, Yaqubi S, Papageorgis P, et al. Epigenetic dysregulation of HTR2A in the brain of patients with schizophrenia and bipolar disorder. Schizophr. Res. 129(2-3), 183-190 (2011).
69. Tang H, Dalton CF, Srisawat U, Zhang ZJ, Reynolds GP. Methylation at a transcription factor-binding site on the 5-HT1A receptor gene correlates with negative symptom treatment response in first episode schizophrenia. Int. J. Neuropsychopharmacol. 17(4), 645-649 (2014).
70. David SP, Murthy NV, Rabiner EA, et al. A functional genetic variation of the serotonin (5-HT) transporter affects 5-HT1A receptor binding in humans. J. Neurosci. 25(10), 2586-2590 (2005